Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19

NCT04373044 is registered in ClinicalTrials.gov with University of Southern California as lead sponsor.

NCT NCT04373044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04373044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19
Lead sponsor
University of Southern California
Phase
Phase 2
Overall status
Terminated
Start date
May 1, 2020
Completion date
May 12, 2021
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

symptomatic covid-19 infection laboratory-confirmed